All In Biotech

Drug Trial Radar · NCT05289323

Effect of Intrathecal Neostigmine on Post-dural Puncture Headache.

Evaluation of Intrathecal Neostigmine as an Adjuvant to Bupivacaine in Ameliorating Post-Dural Puncture Headache in Elective Caesarian Section: A Prospective Randomized Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 722 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

722

Actual

Start

Apr 25, 2022

Primary completion

Jul 25, 2023

Study completion Jul 25, 2023

Sponsor

Lead sponsor
Alexandria UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kasr El Aini Hospital; Fayoum University
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Intravenous neostigmine was recently reported as an effective treatment for PDPH for parturients after intrathecal (IT) block which is postulated to be through its central effects on CSF secretion and cerebral vascular tone modulation. Intrathecal neostigmine has been investigated widely and found to be an effective adjuvant to bupivacaine for postoperative analgesia. The objective of the current study is to investigate the possible prophylactic role of intrathecal neostigmine as an adjuvant to bupivacaine in reducing the incidence and severity of post-dural puncture headache in parturients scheduled for an elective cesarean section.

Conditions

  • Post-Dural Puncture Headache

Interventions

  • Neostigmine MethylsulfateDrug

    0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.

  • Dextrose 5%/Nacl 0.9% InjDrug

    one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of post-dural puncture headacheTime frame: Two times daily for five days after intrathecal block.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alexandria University

    Alexandria, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.